◆英語タイトル:Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020
◆発行会社(調査会社):KuicK Research
Single userUSD2,000 ⇒換算¥206,000見積依頼/購入/質問フォーム
Multi UserUSD4,000 ⇒換算¥412,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。


The outline of human vaccines had an incredible impact on global health system which resulted in intense reduction of mortality and morbidity caused by numerous diseases. Vaccines have led to some of the greatest public health achievements ever, including the eradication of naturally occurring smallpox from the globe and the near eradication of polio. This prophylaxis had a long journey through various roads and tunnels to become the humanities’ key achievement. Despite of the fact, that its mechanism of action remained unclear for centuries. New vaccines coined up in nineteenth century and after the expanded studies of infectious diseases and processed microorganism vaccination has become an intensive subject to be studied. By all the new advances towards the discovery and understanding of various diseases, our species was able to find a way to eradicate them.
In recent years peptides have emerged as the considerable vaccine candidate owning to their simple and cost efficient production & development process. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides represent an excellent starting point for the design of novel therapeutics. Several peptide vaccines are now being designed and are encountering phase I and phase II clinical trials.

Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.

Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment that could help pharmaceutical companies to generate more revenues and help patients to alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate cancer has been introduced in global market. This segment has tendency towards clinical trials as compared to marketed products. Most of the novel products are at different stages of clinical trials which would be introduced in global market in coming years. Biomarkers like Melanoma-Associated Antigen 1 (MAGE-1) for melanoma cancer vaccine and NY-ESO-1 for lung cancer are being developed. Their development requires state-of-art technology due to which they are still not available in market. But confidently these drugs are going to overcome the all hurdles and will become the best suitable candidates in drug market.

A persistent theme in recent peptide based therapeutics is to trigger adaptive antigen specific responses. The next generation drugs will be designed to deliver defined antigenic peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new advantages of their cytokine production in enhancing immune response.This is already evident that in ongoing clinical trials that the benefits of using such vaccines will be large however safety concerns with diseases like cancer and HIV are still under critical observations. With the growing knowledge of immunological mechanism of adjuvant action, including identifying the role of specific signaling pathways peptide based vaccines are going to become more attractive and more effective segment of therapeutics.

Although, the opinions of experts in this field are mixed, it is likely that with new product approvals and advanced research, the field of active peptide immunotherapy is self-assured for dramatic growth in the coming years. Using the gained knowledge and history of passive immunotherapy development as guiding tool, the peptides will revolutionize the market with modern treatment of varied diseases by the means of peptides vaccines.

“Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020” Report Highlights:

• Introduction & Classification of Peptide Vaccines
• Designing & Production of Peptide Vaccine
• Mechanism of Peptide Vaccine
• Cancer Immunotherapy with Peptide Vaccine
• Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
• Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
• Majority vaccines in Preclinical Phase: 28 Vaccines
• Global Peptide Vaccine Market Future Prospects


1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines
1.1 Introduction
1.2 Glimpse of Antiquity

2. Need of Peptide Vaccines
2.1 Why Peptides – More Desirable
2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines
3.1 On the Basis of Sources Obtained
3.2 On the Basis of Length
3.3 On the Basis of Epitopes

4. Designing & Production of Peptide Vaccine
4.1 Synthetic Peptide Vaccine
4.2 Selection of Peptide Antigen
4.3 Construction of Peptide Antigen
4.4 Chemical Synthesis of Peptide Vaccine
4.4.1 Solution Phase Synthesis (SPS)
4.4.2 Solid Phase Peptide Synthesis (SPPS)

5. Mechanism of Peptide Vaccine
5.1 Induction of Immune Response
5.1.1 Factors Affecting T-Cell Stimulation
5.1.2 Factors Affecting B-cell Stimulation
5.1.3 Factors Affecting T-helper Cells
5.2 Delivery System for Peptide Vaccines
5.2.1 Immunostimulatory Adjuvants
5.2.2 Vaccine Delivery System
5.3 Multiple Antigen Peptide System (MAP)
5.3.1 Use of MAP for Foot-and-Mouth Disease

6. Cancer Immunotherapy with Peptide Vaccine
6.1 Peptides as Tumor Antigens
6.2 Immunotherapy with Peptide Vaccination
6.3 Therapeutic Evaluation of Peptide Vaccine
6.3.1 Prostate Cancer
6.3.2 Breast Cancer
6.3.3 Gastric Cancer
6.3.4 Lung Cancer
6.3.5 Pancreatic Cancer

7. Global Peptide Vaccine Market Overview
7.1 Peptide Vaccine – Does have Long & Secure Future?
7.2 Peptide Patents Insights
7.3 Peptide Vaccine Pipeline Overview

8. Global Peptide Vaccine Market Dynamics
8.1 Accelerative Parameters
8.1.1 Peptidomics
8.1.2 Advances in Vaccine Research
8.1.3 Stronger Clinical Pipeline
8.1.4 Emergence of Biologics in Cancer Therapy
8.2 Commercialization Challenges & Modifications
8.2.1 Funding & Legal Issues
8.2.2 Designing & Manufacturing Challenges
8.2.3 Route of Administration
8.2.4 Peptide Pharmacodynamics & Pharmacokinetics

9. Global Peptide Vaccine Market Future Perspectives

10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III

11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
11.1 No Development Reported
11.2 Discontinued
11.3 Market Withdrawal
11.4 Suspended

12. Competitive Landscape
12.1 AFFiRiS
12.2 AlerGenetica
12.3 Anergis
12.4 Antigen Express
12.5 Apitope Technology
12.6 Araclon Biotech
12.7 Artificial Cell Technologies
12.8 Benovus Bio
12.9 Bionor Pharma
12.10 Circassia
12.11 Celgene Corporation
12.12 Galena Biopharma
12.13 Immatics biotechnologies
12.14 Immune Design
12.15 ImmunoCellular Therapeutics
12.16 Invectys
12.17 ISA Pharmaceuticals
12.18 Lytix Biopharma
12.19 Medinet
12.20 Spotlight Innovation (Memcine Pharmaceuticals)
12.21 Merck Serono
12.22 OncoTherapy Science
12.23 Peptech
12.24 Peptinov
12.25 PeptiVir
12.26 Pharmasyntez
12.27 Renaptys Vaccines
12.28 Sumitomo Dainippon Pharma
12.29 TapImmune
12.30 Targovax
12.31 Vaxon Biotech

Figure 1-1: History of Vaccines
Figure 2-1: Peptides - Amino Acid & Proteins
Figure 2-2: Diversification of Vaccines
Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
Figure 3-1: Classification of Peptide Vaccine by Source
Figure 3-2: Classification on Basis of Length
Figure 3-3: On the Basis of Epitopes
Figure 4-1: Synthetic Peptide Manufacturing Process
Figure 4-2: Selection of Synthetic Immunogenic Constructs
Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.
Figure 4-4: Fmoc Cleavage
Figure 4-5: Boc Cleavage
Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells
Figure 5-2: Delivery System Pathways by Adjuvants
Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation.
Figure 6-1: TAAs on the Basis of Tissue Distribution
Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells
Figure 6-3: Mechanism of Action of Sipuleucel-T
Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies
Figure 6-5: Peptides Applied in Treating Cancer
Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020
Figure 7-2: Approved Peptide Drugs
Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016
Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016
Figure 7-5: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016
Figure 7-6: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016
Figure 8-1: Global - Peptide Market Favorable Parameters
Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges
Figure 8-3: Routes of Administration
Figure 12-1: Anergis – Clinical Pipeline
Figure 12-2: Apitope Technology – Clinical Pipeline
Figure 12-3: Benovus Bio – Clinical Pipeline
Figure 12-4: Bionor Pharma – Clinical Pipeline
Figure 12-5: Circassia – Clinical Pipeline
Figure 12-6: Celgene - Clinical Pipeline
Figure 12-7: Galena Biopharma - Clinical Pipeline
Figure 12-8: Immatics Biotechnologies - Clinical Pipeline
Figure 12-9: Immune Design – Clinical Pipeline
Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline
Figure 12-11: Invectys – Clinical Pipeline
Figure 12-12: ISA Pharmaceuticals – Clinical Pipeline
Figure 12-13: Lytix Biopharma - Clinical Pipeline
Figure 12-14: Merck Serono – Clinical Pipeline
Figure 12-15: Onco Therapy Science – Clinical Pipeline
Figure 12-16: Peptinov - Clinical Pipeline
Figure 12-17: Sumitomo Dainippon Pharma – Clinical Pipeline
Figure 12-18: Tapimmune – Clinical Pipeline
Figure 12-19: Targovax - Clinical Pipeline
Figure 12-20: Vaxon Biotech - Clinical Pipeline





※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年10月27日現在 208,454 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。